GAINESVILLE, FL – January 8, 2013
SMART Biotechnologies, Inc., the newest subsidiary of the medical technology innovator, Xhale, Inc., has just appointed Mr. Thomas J. Bigger as its new president. Mr. Bigger comes to SMART with over 20 years of experience building shareholder value in pharmaceutical companies globally. Mr. Bigger most recently held the positions of President and CEO of Paratek Pharmaceuticals in Boston, MA, where he built a fully integrated pharmaceutical company that develops products for serious diseases. He also held senior positions at Magainin Pharmaceuticals, Advanced Polymer Systems and Rhone-Poulenc Rorer.
Mr. Bigger joins SMART Biotechnologies at a crucial and exciting juncture as the company prepares to launch its new product line, the SMART® Adherence System. This breakthrough technology monitors, reports and improves adherence to prescribed medication regimens. The SMART® system is the only technology available that definitively verifies that the right person took the right dose of the right medication at the right time. The SMART® system is patient-centric and noninvasive. Utilizing exhaled breath, the system wirelessly reports – in real time – on medication adherence of participants in clinical trials, allowing immediate intervention when a participant misses a dose.
“We are excited to have Mr. Bigger leading SMART Biotechnologies”, said Richard R. Allen, CEO of Xhale. “There is a tremendous need for SMART® in the industry, and it’s imperative that we execute extraordinarily well on serving our pharmaceutical partners. Tom has the background and expertise we need for this important role.”
Mr. Bigger said, “The SMART® system will have a direct impact on the success of drug approval, and help provide safer, more efficient and effective drug development. We believe the SMART® Adherence System will become the gold standard for monitoring and improving medication adherence in clinical trials and in disease management and prevention”.
Xhale, Inc. is a medical technology innovator, developing products that transform healthcare and save lives. The company is a world leader in the use of sensors that analyze vapor and exhaled breath and is focused on novel patient-centric monitoring solutions. Its current product lines include SMART®, the world’s only definitive medication adherence monitoring system, and Assurance™, a replacement for conventional finger-based pulse oximetry which will monitor multiple patient parameters from a single-point-of-contact sensor, more comfortably and conveniently than finger-based pulse oximetry with fewer false alarms.